Related Experiment Video
Updated: Sep 25, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
[Pathological classification of malignant lymphoma]
1Pathology Division, National Cancer Research Institute.
Insights
Accurate classification of malignant lymphomas, including Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL), is crucial for effective treatment. Current non-Hodgkin's lymphoma classifications need improvement to integrate new scientific understanding for better clinical application.
Area of Science:
- Oncology
- Hematology
- Pathology
Context:
- Accurate diagnosis and classification of malignant lymphomas are critical for guiding patient treatment strategies.
- Distinguishing between Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) is essential due to their differing clinical behaviors and therapeutic responses.
- Existing classification systems for non-Hodgkin's lymphoma (NHL) primarily rely on morphology and require enhancement to incorporate modern biological insights.
Purpose:
- To highlight the importance of precise lymphoma classification in clinical practice.
- To underscore the limitations of current non-Hodgkin's lymphoma (NHL) classification systems.
- To advocate for the development of improved, histogenetically accurate, and clinically relevant lymphoma classifications.
Summary:
- Malignant lymphoma classification is pivotal for treatment selection, necessitating clear differentiation between Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
- While Hodgkin's disease (HD) subtypes exist, their clinical significance is limited compared to the need for advanced classification of non-Hodgkin's lymphoma (NHL).
- Current non-Hodgkin's lymphoma (NHL) classifications, largely morphology-based, must evolve to integrate current understanding of lymphoma cell biology for improved accuracy and clinical utility.
Impact:
- Facilitates more targeted and effective therapeutic interventions for lymphoma patients.
- Drives the development of next-generation lymphoma classification systems.
- Enhances the precision of oncological and hematological diagnoses, improving patient outcomes.
Abstract:
The classification of malignant lymphoma is an important factor in treatment. Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) should be clearly differentiated from each other, since their clinical behavior and response to treatment are quite different. Although four histological subtypes of HD has been recognized, the subclassification is not so important clinically. Many classifications of NHL have been devised, but most of them are based on morphological features only and do not incorporate recent advances in understanding of origin, function and differentiation of lymphoma cells. Further improvement is necessary to establish a reproducible, histogenetically accurate and clinically meaningful classification.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation
Classification of Leukocytes
Neutrophils are the most abundant type of granular leukocytes, comprising 50-70% of all leukocytes. They feature small, evenly distributed granules and a...
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

